Page 188 - Clinical Immunology_ Principles and Practice ( PDFDrive )

170 ParT ONE Principles of Immune Response

6. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 23. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in
coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol secondary lymphoid organs. Annu Rev Immunol 2005;23:127–59.
1999;17:657–700. 24. Tubo NJ, McLachlan JB, Campbell JJ. Chemokine receptor requirements
7. Deruaz M, Frauenschuh A, Alessandri AL, et al. Ticks produce highly for epidermal T-cell trafficking. Am J Pathol 2011;178:2496–503.
selective chemokine binding proteins with antiinflammatory activity. J 25. Zhang HH, Song K, Rabin RL, et al. CCR2 identifies a stable population
Exp Med 2008;205:2019–31. of human effector memory CD4β T cells equipped for rapid recall
8. Schumann K, Lammermann T, Bruckner M, et al. Immobilized response. J Immunol 2010;185:6646–63.
chemokine fields and soluble chemokine gradients cooperatively shape 26. Singh SP, Zhang HH, Foley JF, et al. Human T cells that are able to
migration patterns of dendritic cells. Immunity 2010;32:703–13. produce IL-17 express the chemokine receptor CCR6. J Immunol
9. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps 2008;180:214–21.
to specificity and diversity. Cell 1991;67:1033–6. 27. Koenecke C, Forster R. CCR9 and inflammatory bowel disease. Expert
10. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Opin Ther Targets 2009;13:297–306.
Immunity 2014;41:694. 28. Singh IP, Chauthe SK. Small molecule HIV entry inhibitors: part I.
11. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Chemokine receptor antagonists: 2004–2010. Expert Opin Ther Pat
Immunol 2008;9:953–9. 2011;21:227–69.
12. Mortier A, Gouwy M, Van Damme J, et al. Effect of posttranslational 29. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by
processing on the in vitro and in vivo activity of chemokines. Exp Cell CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med
Res 2011;317:642–54. 2009;360:692–8.
13. Martin C, Burdon PC, Bridger G, et al. Chemokines acting via CXCR2 30. Lim JK, Murphy PM. Chemokine control of West Nile virus infection.
and CXCR4 control the release of neutrophils from the bone marrow and Exp Cell Res 2011;317:569–74.
their return following senescence. Immunity 2003;19:583–93. 31. Gaur D, Mayer DC, Miller LH. Parasite ligand-host receptor interactions
14. Schulz O, Hammerschmidt SI, Moschovakis GL, et al. Chemokines and during invasion of erythrocytes by Plasmodium merozoites. Int J Parasitol
chemokine receptors in lymphoid tissue dynamics. Annu Rev Immunol 2004;34:1413–29.
2016;34:203. 32. Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency
15. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine disease. Curr Opin Hematol 2009;16:20–6.
receptors in inflammation. N Engl J Med 2006;354:610–21. 33. Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an
16. Vandercappellen J, Van Damme J, Struyf S. The role of the CXC SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem
chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/ and progenitor cells. Curr Opin Hematol 2010;17:319–26.
PF- 4var) in inflammation, angiogenesis and cancer. Cytokine Growth 34. McDermott DH, Liu Q, Velez D, et al. A phase 1 clinical trial of
Factor Rev 2011;22:1–18. long-term, low-dose treatment of WHIM syndrome with the CXCR4
17. Stillie R, Farooq SM, Gordon JR, et al. The functional significance behind antagonist plerixafor. Blood 2014;123:2308.
expressing two IL-8 receptor types on PMN. J Leukoc Biol 35. McDermott DH, Gao JL, Liu Q, et al. Chromothriptic cure of WHIM
2009;86:529–43. syndrome. Cell 2015;160:686.
18. Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade 36. Koenen RR, Weber C. Chemokines: established and novel targets in
drives neutrophil recruitment in a murine model of inflammatory atherosclerosis. EMBO Mol Med 2011;3:713.
arthritis. Immunity 2010;33:266–78. 37. Grisotto MG, Garin A, Martin AP, et al. The human herpesvirus 8
19. Geissmann F, Mass E. A stratified myeloid system, the challenge of chemokine receptor vGPCR triggers autonomous proliferation of
understanding macrophage diversity. Semin Immunol 2015;27:353. endothelial cells. J Clin Invest 2006;116:1264–73.
20. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: 38. Cuker A. Recent advances in heparin-induced thrombocytopenia. Curr
positioning cells for host defense and immunity. Annu Rev Immunol Opin Hematol 2011;18:315–22.
2014;32:659. 39. Allavena P, Germano G, Marchesi F, et al. Chemokines in cancer related
21. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing inflammation. Exp Cell Res 2011;317:664.
immunity and tolerance. Nat Rev Immunol 2008;8:362–71. 40. Proudfoot AE, Bonvin P, Power CA. Targeting chemokines: pathogens
22. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on can, why can’t we? Cytokine 2015;74:259.
lymphoid organ development and systemic immunity. Immunol Rev
2003;195:117–35.